Helena Maria Hoen

Title: Helena Maria Hoen: Innovator in Cancer Immunotherapy

Introduction

Helena Maria Hoen is a prominent inventor based in Portland, OR (US). She has made significant contributions to the field of cancer immunotherapy, particularly in the development of predictive biomarkers for treatment efficacy. Her work is vital for improving patient outcomes in cancer therapy.

Latest Patents

Helena holds a patent titled "CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy." This patent outlines methods for selecting cancer patients for anti-CTLA-4 immunotherapy based on the measured levels of CXCL11 and/or sMICA. These methods are instrumental in predicting whether a patient will respond positively to the treatment, thereby enhancing overall survival rates. The patent also includes methods for treating patients with anti-CTLA-4 immunotherapy after testing for these biomarkers.

Career Highlights

Throughout her career, Helena has worked with notable organizations such as Bristol-Myers Squibb Company and Providence Health & Services. Her experience in these companies has allowed her to contribute to groundbreaking research and development in cancer treatment.

Collaborations

Helena has collaborated with esteemed colleagues, including Keith Sadoon Bahjat and Yoshinobu Koguchi. These partnerships have furthered her research and innovation in the field of immunotherapy.

Conclusion

Helena Maria Hoen is a trailblazer in cancer immunotherapy, with her innovative patent and collaborations paving the way for advancements in patient care. Her work exemplifies the impact of scientific research on improving treatment outcomes for cancer patients.